Weitai Medical -B(02235) announced that the company issued 63,529,500 shares. The issue price per share is HK$ 30.5 (the same below).
Assuming that the over-allotment option is not exercised, the net income is 65.438+08.65438+05 billion yuan. Each lot 100 shares, it is expected that 10 and 19 will be listed. The company's public offering was subscribed by 6.79 times. The final number of shares issued this time is 6.353 million shares, accounting for about 10% of the total number of shares issued this time (before exercising any over-allotment option).
In addition, the final number of shares offered under the international offering is 57 176500, which is equivalent to about 90% of the total number of shares offered (before exercising any over-allotment right).
Weitai Medical was established on 20 1 1, mainly engaged in the research and development and production of medical devices for diabetes treatment and diabetes monitoring.
At present, Weitai Medical has three products on sale, namely: Equil patch insulin pump, which has been listed in China and the European Union; AiDEX G7 continuous blood glucose monitoring system, only listed in the EU; IVD blood glucose monitoring system products have been listed in China, the United States and the European Union. According to financial data, in 20 19 and 2020, Weitai Medical recorded income of 518.63 million yuan and 75.277 million yuan respectively. The net losses in the same period were 7.861.4 million yuan and 1.25438+0 billion yuan respectively; 202 1 In the first four months, the company realized revenue of 3885 1 10,000 yuan and net loss of 2,586,438+0,000 yuan.
Although three core products, such as Equil, have been listed, the losses of Weitai Medical are still expanding. The two-year loss was nearly 200 million yuan, which was mainly caused by the increase of management expenses, R&D expenses, sales and distribution expenses during the reporting period.
Weitai Medical is the only company in the world that has both an approved patch insulin pump and a calibration-free continuous blood glucose monitoring system.
In 20 19 and 2020, the proportion of Equil product revenue to the company's total revenue was 47.6% and 46.2%, respectively, showing a slight downward trend; The income of blood glucose monitoring system accounts for 52.0% and 52.2% of the total income respectively, which makes a great contribution to the income.
：
At present, there are two kinds of insulin pumps in the market: pipeline insulin pump and paste insulin pump.
Compared with the traditional pipeline insulin pump, the pipeline-free adhesive insulin pump has no catheter, which can avoid many problems caused by the catheter, and the equipment is smaller and more portable.
The main disadvantage is that it is expensive. In China, the average daily cost of patients who use Equil is about 32 yuan to 36 yuan, while the average daily cost of patients who use traditional insulin syringes or pens is only about 7 yuan to 10 yuan. It is not difficult to understand that traditional diabetes treatment equipment still occupies most of the market share.
From the perspective of industry, the demand for medical devices for diabetes will increase. The data shows that the number of diabetic patients in China was1190,000 in 20 19 years, and it is expected to reach1430,000 in 2030. The market size of diabetic medical devices in China is expected to increase from 900 million dollars in 2020 to 3.6 billion dollars in 2030, with a compound annual growth rate of 15. 1%.